Story perspectives

Amgen Acquires Dark Blue Therapeutics for $840 Million

1/7/2026

Summary

Story summary

Amgen has finalized the acquisition of Dark Blue Therapeutics for up to $840 million amid impending patent expirations for Prolia and Kyprolis.
Dark Blue Therapeutics, based in Oxford, United Kingdom, develops protein degrader therapies for proteins linked to acute myeloid leukemia, with lead compound DBT 3757 showing preclinical activity.
Alastair MacKinnon, Dark Blue Therapeutics CEO, said Amgen's resources could advance their research and deliver new treatment options for patients.

1 of 1

Story summary

Amgen has finalized the acquisition of Dark Blue Therapeutics for up to $840 million amid impending patent expirations for Prolia and Kyprolis.
Dark Blue Therapeutics, based in Oxford, United Kingdom, develops protein degrader therapies for proteins linked to acute myeloid leukemia, with lead compound DBT 3757 showing preclinical activity.
Alastair MacKinnon, Dark Blue Therapeutics CEO, said Amgen's resources could advance their research and deliver new treatment options for patients.